Skip to main content
Tellgen Corporation logo

Tellgen Corporation — Investor Relations & Filings

Ticker · 300642 ISIN · CNE100002P42 LEI · 30030027IMY7UJOVB424 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,386 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300642

About Tellgen Corporation

https://www.tellgen.com

Tellgen Corporation specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products. The company focuses on high-throughput multiplex testing solutions, utilizing advanced technologies such as liquid chip platforms and multiplex PCR. Its product portfolio encompasses a wide range of clinical applications, including oncology screening, infectious disease detection, cardiovascular health assessment, and genetic testing. Tellgen is recognized for its proprietary multiplexing technology, which allows for the simultaneous detection of multiple biomarkers in a single sample, enhancing diagnostic efficiency and accuracy. The company provides comprehensive diagnostic systems, including reagents and automated instrumentation, to clinical laboratories and healthcare institutions. By integrating molecular and immunodiagnostic methodologies, Tellgen supports early disease detection and personalized medicine initiatives.

Recent filings

Filing Released Lang Actions
关于全资子公司申报医疗器械注册获得受理的公告
Regulatory Filings Classification · 82% confidence The document is an exchange announcement (公告) reporting that a wholly-owned subsidiary’s medical device registration application has been accepted by the provincial drug administration. It is not a financial report, dividend notice, share transaction, management change, or any other specific category. It falls under general regulatory or compliance announcements, which defaults to Regulatory Filings (RNS).
2026-06-04 Chinese
关于申报医疗器械注册获得受理的公告
Regulatory Filings Classification · 78% confidence The document is an official corporate announcement by Shanghai TuoJing Life Technology Co. regarding the acceptance of its medical device registration application by the national drug regulatory authority. It contains no financial statements, management changes, or shareholder votes; rather it is a compliance/regulatory status update. This fits the fallback category for general regulatory announcements (RNS).
2026-05-25 Chinese
关于控股子公司通过高新技术企业重新认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (620 characters) from Shanghai Toujing Life Technology Co., Ltd. regarding the re-certification of its subsidiary as a high-tech enterprise, including tax benefits and certificate details. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official regulatory announcement about a tax status update and certificate issuance. The document is not a full report but a regulatory announcement about a corporate event. Therefore, it fits best under Regulatory Filings (RNS).
2026-05-19 Chinese
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement from Shanghai Toujing Life Technology Co., Ltd. regarding the implementation of the 2025 annual equity distribution (dividend payment). It details the dividend amount per 10 shares, the total cash dividend, the record date, the ex-dividend date, and the shareholders entitled to receive the dividend. It also references the shareholders' meeting approval of the dividend plan and provides procedural details for dividend distribution. The document is relatively short (2793 characters) and primarily serves as a formal notice of the dividend distribution implementation rather than a full financial report or detailed analysis. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2026-05-19 Chinese
关于取得发明专利证书的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement disclosing the grant of an invention patent certificate by a subsidiary. It contains no financial data, meeting materials, or report attachments, nor does it pertain to director changes, dividends, share transactions, or earnings. It is a standard regulatory disclosure of intellectual property status and thus falls under general regulatory filings.
2026-05-18 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 97% confidence The document is titled as a 2025 shareholder meeting resolutions announcement (“2025年度股东会决议公告”) and provides detailed voting results for ten proposals, including vote counts and percentages. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-15 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.